ARTICLE | Finance
Behind Jeito’s decision to back Glick-led Odyssey
The $213M, oversubscribed series D reflects investor conviction in high-caliber founder and differentiated autoimmune pipeline
September 11, 2025 10:36 PM UTC
Updated on Sep 16, 2025 at 5:48 PM UTC
The track record of serial biotech entrepreneur Gary Glick, together with a RIPK2 program and the promise of a growing autoimmune market, convinced European VC Jeito to invest in Odyssey’s oversubscribed $213 million series D round.
It was a competitive round, Jeito Capital Partner & Chief Commercial Officer Ksenija Pavletic told BioCentury. “When you’re Gary Glick you get to choose your investors.”...